Zevra Therapeutics (ZVRA) Long-Term Investments (2016 - 2026)

Zevra Therapeutics has reported Long-Term Investments for 7 years, with the latest figure at $36.1 million in Q1 2026.

• For the quarter ending Q1 2026, Long-Term Investments rose 493.42% year-over-year to $36.1 million; the trailing twelve-month figure through Mar 2026 stood at $36.1 million (up 493.42% YoY), and the FY2025 full-year result was $47.9 million, up 696.66% from the prior year.
• Long-Term Investments for Q1 2026 stood at $36.1 million, down from $47.9 million in the prior quarter.
• The five-year high for Long-Term Investments was $47.9 million in Q4 2025, with the low at $6.0 million in Q4 2024.
• Historically, Long-Term Investments has averaged $22.8 million across 4 years, with a median of $20.0 million in 2022.
• Annual changes were most pronounced in 2022 — Long-Term Investments soared 33.94% — and 2025, when it jumped 696.66%.
• Zevra Therapeutics' Long-Term Investments stood at $20.0 million in 2022, then sank by 69.95% to $6.0 million in 2024, then jumped by 696.66% to $47.9 million in 2025, then fell by 24.51% to $36.1 million in 2026.
• The last three Long-Term Investments figures came in at $36.1 million (Q1 2026), $47.9 million (Q4 2025), and $30.9 million (Q3 2025), per Business Quant data.